Virus inactivator

Abstract

To provide a virus inactivator that enables inactivation of viruses existing in the environment.SOLUTION: A virus inactivator comprising a combination of the following components (A) and (B): (A) thymol; and (B) at least one selected from an ester of cedrol represented by the following formula (b1), an ester of β-caryophyllene alcohol represented by the following formula (b2), an ester of citronellol represented by the following formula (b3), trans-2-undecenal, and intreleven aldehyde, where R1, R2, and R3 each independently represent a straight-chain or branched alkyl group or alkenyl group having 1 to 4 carbon atoms.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a virus inactivator for inactivating viruses.

Background Art

[0002] Viral infectious diseases are diseases that start with cold symptoms and cause severe symptoms such as pneumonia, hepatitis, and encephalitis, and pose an eternal threat to humanity. In recent years, influenza viruses have raged worldwide, and sometimes pandemics occur due to the emergence of new influenza with changed antigenicity. In 2019, SARS-CoV-2 emerged, causing a pandemic that has affected not only lives and health but also economic activities and social functions.

[0003] To address such situations, vaccines and antiviral agents have been developed, but the development of vaccines and therapeutic agents takes time and is not always successful.

[0004]

[0005] When a virus is brought into the living space by an infected person, the infection spreads directly from the patient or through the environment including clothes, various instruments and members, and facilities such as walls and air conditioners. Therefore, it is considered effective to prevent the spread of infection by removing or inactivating the virus by cleaning and disinfecting fingers, clothes, various instruments and members to which the virus can adhere, and inactivating the virus that has been splashed into the living space and floating in the air as aerosols. Conventionally, ethanol, sodium hypochlorite, chlorine dioxide, glutaraldehyde, etc. have been used for the purpose of inactivating viruses. However, these common disinfectants have high irritation to mucous membranes and skin, so their uses are limited due to safety problems. In addition, as a method of chemically inactivating viruses existing in space, spraying chlorine dioxide has also been devised, but its effect is not certain.Essential oils and the fragrance components contained therein are incorporated into various products, starting with cosmetics as fragrances. It is well known that there are essential oils and compounds that exhibit specific physiological effects. As essential oils and compounds having antiviral activity, for example, it has been reported that thymol has an action of inhibiting the binding between human and simian immunodeficiency viruses and target cells (Non-Patent Document 1).

Prior Art Documents

Non-Patent Documents

[0006]

Non-Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0007] The present invention relates to providing a virus inactivator that enables more effectively inactivating viruses present in the environment.

Means for Solving the Problems

[0008] The present inventors have found that a specific combination of compounds containing thymol effectively inactivates influenza viruses and that these are useful as virus inactivators.

[0009] That is, the present invention relates to the following 1) to 3). 1) A virus inactivator comprising a combination of the following components (A) and (B); (A) Thymol, (B) One or more selected from esters of cedrol represented by the following formula (b1), esters of β-caryophyllene alcohol represented by the following formula (b2), esters of citronellol represented by the following formula (b3), trans-2-undecenal, and interlabenal. 2) An antiviral composition containing the following components (A) and (B): (A) Thymol, (B) One or more selected from cedrol esters represented by the following formula (b1), β-caryophyllene alcohol esters represented by the following formula (b2), citronellol esters represented by the following formula (b3), trans-2-undecenal, and interlebenaldehyde. 3) A method for inactivating viruses, comprising applying the following components (A) and (B), or a composition containing them, to an object where viral contamination is a concern: (A) Thymol, (B) One or more selected from cedrol esters represented by the following formula (b1), β-caryophyllene alcohol esters represented by the following formula (b2), citronellol esters represented by the following formula (b3), trans-2-undecenal, and interlebenaldehyde.

[0010] [ka] [In the formula, R 1 , R 2 , R 3 represents a linear or branched alkyl or alkenyl group having 1 to 4 carbon atoms. [Effects of the Invention]

[0011] The virus inactivating agent of the present invention can more effectively inactivate viruses attached to hard or soft surfaces in the living environment, viruses dispersed in droplets in living spaces, and viruses floating in the air as aerosols, compared to when each component is used separately, thereby preventing or reducing the spread of infection caused by the viruses. DETAILED DESCRIPTION OF THE INVENTION

[0012] The virus inactivating agent of the present invention comprises a combination of the following components (A) and (B): (A) Thymol, (B) At least one selected from esters of cedrol represented by the following formula (b1), esters of β-caryophyllene alcohol represented by the following formula (b2), esters of citronellol represented by the following formula (b3), trans-2-undecenal, and interlabenal aldehyde.

[0013]

Chemical formula

[0014] The linear or branched alkyl group or alkenyl group having 1 to 4 carbon atoms represents a group selected from a linear alkyl group having 1 to 4 carbon atoms, a branched alkyl group having 1 to 4 carbon atoms, a linear alkenyl group having 1 to 4 carbon atoms, and a branched alkenyl group having 1 to 4 carbon atoms.

[0015] The combination of component (A) and component (B) is carried out by mixing component (A) and component (B) in an appropriate mass ratio in advance or at the time of use. As one aspect, component (A) and component (B) are combined into a single preparation (for example, an antiviral composition), and as another aspect, for example, preparations containing component (A) and component (B) are prepared separately and combined at the time of use.

[0016] In the present invention, the virus inactivator may be a virus infection reducing agent. Also, the virus inactivating effect may be a virus infection reducing effect.

[0017] Both component (A) and component (B) of the present invention are commercially available compounds as fragrances. Thymol of component (A) has the chemical name 5-methyl-2-(1-methylethyl)phenol. "Thymol" is commercially available from Tokyo Chemical Industry Co., Ltd. and others.

[0018] Examples of the ester of cedrol represented by the formula (b1) of the component (B) include, for example, cedryl acetate (R 1 = methyl group), cedryl propionate (R 1 = ethyl group), cedryl butyrate (R 1 = propyl group), cedryl isobutyrate (R 1 = isopropyl group), cedryl valerate (R 1 = butyl group), etc. From the viewpoint of the virus inactivating effect, an ester in which R 1 is a linear alkyl group having 1 to 3 carbon atoms is preferable, and cedryl acetate is more preferable.

[0019] Examples of the ester of β-caryophyllene alcohol represented by the formula (b2) of the component (B) include, for example, caryophyllene acetate (R 2 = methyl group), caryophyllene propionate (R 2 = ethyl group), caryophyllene butyrate (R 2 = propyl group), caryophyllene isobutyrate (R 2 = isopropyl group), caryophyllene valerate (R 2 = butyl group), etc. From the viewpoint of the virus inactivating effect, an ester in which R 2 is a linear alkyl group having 1 to 3 carbon atoms is preferable, and caryophyllene acetate is more preferable.

[0020] Examples of the ester of citronellol represented by the formula (b3) of the component (B) include, for example, citronellyl acetate (R 3 = methyl group), citronellyl propionate (R 3 = ethyl group), citronellyl butyrate (R 3 = propyl group), citronellyl isobutyrate (R 3 = isopropyl group), citronellyl valerate (R 3 = butyl group), citronellyl tiglate (R 3 = 2-butenyl group), etc. From the viewpoint of the virus inactivating effect, an ester in which R 3 is a linear or branched alkyl group or alkenyl group having 3 to 4 carbon atoms is preferable, and citronellyl butyrate is preferable.

[0021] Component (B) is commercially available, for example, as follows. · Cedryl acetate (alias: Cedryl acetate): Sigma-Aldrich · Caryophyllene acetate: Givaudan · Citronellyl propionate (alias: Citronellyl propionate): Fujifilm Wako Pure Chemical Corporation · Citronellyl butyrate (alias: Citronellyl butyrate): Tokyo Chemical Industry Co., Ltd. · Citronellyl isobutyrate (alias: Citronellyl isobutyrate): Fujifilm Wako Pure Chemical Corporation · Citronellyl isovalerate (alias: Citronellyl isovalerate): Fujifilm Wako Pure Chemical Corporation · Citronellyl tiglate (alias: Citronellyl tiglate): Sigma-Aldrich · trans-2-Undecenal (alias: (E)-Undec-2-enal): Bedoukian Research · Interlevenal: International Flavors & Fragrances

[0022] From the viewpoint of improving the virus inactivation effect (hereinafter also referred to as the virus inactivation effect aspect), the ratio of component (B) to component (A) (B / A) is preferably 0.05 or more, more preferably 0.1 or more, still more preferably 0.15 or more, and preferably 20 or less, more preferably 15 or less, still more preferably 10 or less on a mass basis. Also, from the same viewpoint, the same ratio (B / A) is preferably 0.05 to 20, more preferably 0.1 to 15, still more preferably 0.15 to 10.

[0023] As shown in the examples described below, when component (A) and component (B) are combined (total concentration 0.1% by mass) and brought into contact with influenza virus in the liquid phase, the viral infectivity titer is significantly reduced, showing an excellent virus inactivation effect. Therefore, the combination of components (A) and (B) can be a virus inactivator. Alternatively, the combination of components (A) and (B) can be used to produce a virus inactivator. In addition, the combination of components (A) and (B) can be used to inactivate viruses.

[0024] The viruses targeted by the virus inactivator of the present invention include all types of viruses regardless of the type of nucleic acid (RNA, DNA) and the presence or absence of an envelope, but pathogenic viruses that infect animals such as humans, livestock, and poultry are preferred. For example, viruses having an envelope include influenza virus, coronavirus, SARS coronavirus, SARS coronavirus-2, RS virus, mumps virus, Lassa virus, dengue virus, rubella virus, human immunodeficiency virus, which have RNA as nucleic acid, and human herpes virus, vaccinia virus, hepatitis B virus, etc., which have DNA as nucleic acid. In addition, viruses having no envelope include norovirus, poliovirus, echovirus, hepatitis A virus, hepatitis E virus, rhinovirus, astrovirus, rotavirus, coxsackievirus, enterovirus, sapovirus, which have RNA as nucleic acid, and adenovirus, B19 virus, papovavirus, human papillomavirus, etc., which have DNA as nucleic acid.

[0025] Among these, viruses having an envelope are preferred, viruses having an envelope and having RNA as nucleic acid are more preferred, and influenza virus, human coronavirus, SARS coronavirus, and SARS coronavirus-2 are more preferred. Note that SARS coronavirus-2 (Severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) is a SARS-related coronavirus that causes acute respiratory disease (COVID-19).

[0026] In the present invention, virus inactivation means an action of reducing or eliminating the activity of a virus and eliminating its infectivity to host cells. Incidentally, the virus inactivation action can be confirmed, for example, by measuring the virus infectivity titer after contacting a test article with a virus and then infecting the virus to host cells. Here, as the host cells, any cells capable of growing the target virus may be used. For influenza virus, for example, canine kidney cells (MDCK), African green monkey kidney epithelial cells (Vero), duck embryo stem cell-derived immortalized cells (EB66) can be used. For human coronavirus, for example, human ileocecal adenocarcinoma cells (HCT-8), African green monkey kidney epithelial cells (VeroE6), human liver cancer-derived immortalized cells (Huh7) can be used.

[0027] The virus inactivator of the present invention may be used in a mode of combining component (A) and component (B) at the time of use, or may be used as a composition (for example, an antiviral composition) containing these. That is, the virus inactivator of the present invention can be an antiviral composition that exhibits a virus inactivation effect, or can be a material or preparation for blending into these. Further, the virus inactivator of the present invention may be used in either a liquid phase state or a gas phase state.

[0028] The above antiviral composition used in the liquid phase state may contain, in addition to components (A) and (B), antibacterial substances such as hypochlorous acid, hydrogen peroxide, silver ion compounds, cationic antibacterial agents (such as benzethonium chloride), fungicides (such as triclosan, isopropylmethylphenol), ethanol, surfactants, etc., and may be appropriately blended with additives such as chelating agents, humectants, lubricants, builders, buffers, abrasives, electrolytes, bleaching agents, fragrances, dyes, foam control agents, corrosion inhibitors, essential oils, thickeners, pigments, gloss improvers, enzymes, detergents, solvents, dispersants, polymers, silicones, water-attracting substances, etc. The form of such a composition can be in the form of liquid, emulsion, cream, lotion, paste, gel, sheet (substrate-supported), oil, etc., but is not limited thereto. The antiviral composition can be appropriately incorporated into various detergents (such as laundry detergents, household detergents, dishwashing detergents, shampoos, hand cleaners, body cleaners, etc.), disinfectants, hygiene product compositions, etc. for use.

[0029] Examples of the above-mentioned hygiene product compositions include lotions, creams, shampoos, hair conditioners, hand soaps, body shampoos, facial cleansers, bath salts, foams, antiperspirants, deodorants, axillary odor preventives, oral hygiene products (such as mouthwashes, toothpastes, oral fresheners, gargles, etc.). The composition can be prepared by appropriately combining carriers acceptable as cosmetics, etc. (such as diluents, dispersants, buffers, pH adjusters, dispersants, emulsifiers, surfactants, preservatives, stabilizers, antioxidants, colorants, moisturizers, thickeners, bactericides, fragrances, etc.) according to conventional methods.

[0030] The antiviral composition used in the gas phase (such as a composition for space virus removal) can be in the form of a liquid or a gel, etc., but a liquid form is preferred. In addition to components (A) and (B), the composition can be prepared by incorporating a base material and various additives (such as polyols (dipropylene glycol, propylene glycol, etc.), surfactants, ultraviolet absorbers, antioxidants, preservatives, deodorants, natural extracts, silicones, thickeners, dyes, pigments, colorants, oils, fragrances, etc.). Here, as the base material, regardless of whether it is oily or aqueous, conventionally known ones such as water, methanol, ethanol, propanol, isopropanol, butanol, isobutanol, dimethyl ether, liquid propane, petrolatum, lanolin, castor oil, paraffinic hydrocarbons (such as liquid paraffin, etc.) can be mentioned, and they can be used alone or in combination of two or more. In the case of making a gel preparation, for example, it can be prepared by appropriately adding water-soluble gelling agents such as carrageenan and gellan gum, oil-soluble gelling agents such as metal soaps and aluminum octylate, natural gelling agents or synthetic gelling agents according to conventionally known methods.

[0031] The content of component (A) relative to the total amount of the composition is preferably 0.0001% by mass or more, more preferably 0.005% by mass or more, still more preferably 0.01% by mass or more from the viewpoint of virus inactivation, and preferably 5% by mass or less, more preferably 3% by mass or less, still more preferably 1% by mass or less from the viewpoint of reducing the aroma intensity. Also, from the same viewpoints, it is preferably 0.0001 to 5% by mass, more preferably 0.005 to 3% by mass, still more preferably 0.01 to 1% by mass.

[0032] The content of component (B) relative to the total amount of the composition is preferably 0.01% by mass or more, more preferably 0.02% by mass or more, still more preferably 0.03% by mass or more from the viewpoint of virus inactivation, and preferably 5% by mass or less, more preferably 3% by mass or less, still more preferably 1% by mass or less from the viewpoint of reducing the aroma intensity. Also, from the same viewpoints, it is preferably 0.01 to 5% by mass, more preferably 0.02 to 3% by mass, still more preferably 0.03 to 1% by mass.

[0033] The total content of component (A) and component (B) relative to the total amount of the composition is preferably 0.01% by mass or more, more preferably 0.03% by mass or more, still more preferably 0.05% by mass or more from the viewpoint of the virus inactivation effect. Also, preferably 5% by mass or less, more preferably 3% by mass or less, still more preferably 1% by mass or less from the viewpoint of reducing the aroma intensity. Also, from the same viewpoints, preferably 0.01 to 5% by mass is preferred, more preferably 0.03 to 3% by mass, still more preferably 0.05 to 1% by mass.

[0034] According to the virus inactivator of the present invention, it is possible to inactivate the virus adhering to the skin or mucous membranes of animals contaminated with the virus, the hard or soft surfaces of inanimate objects, objects such as waste, etc., or the virus that has splashed into the living space. Here, examples of the surface of inanimate objects include hard surfaces such as counters, sinks, restrooms, toilets, bathtubs, shower stalls, floors, windows, doorknobs, walls, drains, pipes, garbage collection areas, etc. in homes and business facilities; hard surfaces such as garbage inlets, work surfaces, switch surfaces, etc. of special vehicles such as garbage trucks and sanitation vehicles; hard surfaces such as floors, handrails, door surfaces, etc. of transport vehicles such as railway vehicles and aircraft fuselages; hard surfaces of various utensils, tools, sundries such as kitchen utensils, furniture, telephones, toys, etc.; and soft surfaces such as textile products (carpets, area rugs, curtains, seats, fabric furniture, clothing, etc.). Examples of waste include general waste (household waste such as food residues, tissue paper, masks, etc.) and industrial waste (sludge, manure, medical waste, etc.). When the waste is contained in a bag, the bag surface may also be the target. In addition, examples of living spaces include inside general households such as dining kitchens, bedrooms, children's rooms, bathrooms, toilets, etc.; inside facilities such as sales stores, cafeterias, hotels, hospitals, workplaces, factories, livestock farms, etc.; inside vehicles such as automobiles, trains, airplanes, etc.; and semi-closed spaces (lockers, storerooms, closets, etc.; storage boxes (for toys, karaoke microphones, tableware, seasonings, writing utensils, stationery, etc.)).

[0035] In the virus inactivator of the present invention, the components (A) and (B), or the composition containing them, are applied to the object where virus contamination is a concern, but the mode is not particularly limited. The components (A) and (B), or the composition containing them, may be brought into contact with or reacted with the virus in the gas phase or liquid phase. As a method of bringing the components (A) and (B) into contact with the virus in the liquid phase, there may be any of the following methods: applying the components (A) and (B), or the composition containing them, directly to the object to be treated; diffusing the components (A) and (B), or the composition containing them, and sprinkling them on the object to be treated; or wiping the target surface with a sheet, gauze, towel, wet wipe, tissue, wet tissue, etc. impregnated with the components (A) and (B), or the composition containing them. Furthermore, the component (A) and (B), or the composition containing them, can be filled into a container or device for atomization or diffusion, such as a pressure liquid spray, a pressurized air atomizing spray device, a diffuser, a nebulizer, etc., and sprayed in a mist form into the space where the virus exists for use. By doing so, the volatilization rate can be increased, and the virus inactivation effect can be rapidly exerted. Also, the same effect can be obtained when the component (A) and (B), or the composition containing them, is used in the form of an aerosol, a mist spray, etc.

[0036] As a method for contacting or reacting the component (A) and (B), or the composition containing them, with the virus in the gas phase, it may be in any form of natural volatilization or forced volatilization of the component (A) and (B). If it is in the form of natural volatilization of the component (A) and (B), the virus existing in the space can be inactivated simply by leaving it in the living space, and the virus in the space can be easily removed (virus elimination). When the virus inactivator of the present invention is used for the purpose of natural volatilization, for example, conventionally known methods such as a method of impregnating a mandrel, filter paper, etc. with component (A) and component (B), or a composition containing these and volatilizing them, or a method of volatilizing them using a permeable membrane can be applied. Further, component (A) and (B), or a composition containing these can also be kneaded with a resin and used. Examples of resins that can be kneaded include natural, petroleum-based, and synthetic waxes, rosin-based resins, ethylene-vinyl acetate copolymers, ethylene-vinyl alcohol copolymers, polyesters, polyolefins, acrylic resins, and the like. The above kneaded product can be used as it is, or can be supported on a porous carrier, formed into a sheet, or used as a laminate of the sheet-like material. Examples of the porous carrier include those obtained by shaping natural polymers such as cellulose and chitosan, the above synthetic resins, and inorganic porous substances such as calcium silicate into any shape such as granular or sheet-like. The above kneaded product or laminate can be installed, for example, in air-conditioning equipment, toilets, bathrooms, living rooms, hospital rooms, hospital waiting rooms, dust boxes, etc., and used while gradually volatilizing component (A) and (B). Further, component (A) and (B), or a composition containing these can also be supported on a product made of paper, non-woven fabric, etc. (such as a filter of an air purifier) and used. When component (A) and (B) are used by forced volatilization, examples of such means include a method of volatilizing using a fan or the like, a heating volatilization method using a heater or the like, a method of volatilizing by ultrasonic waves, and the like.

[0037] In addition, when performing virus removal treatment in a space, the usage amounts of component (A) and (B), or the composition containing these, can be appropriately adjusted according to the treatment mode, space environment such as temperature and humidity, vapor pressure of component (A) and (B), etc., and it is also possible to make the concentration in the space of component (A) and (B) equal to or higher than the saturation concentration. However, for example, from the viewpoint of the virus inactivation effect, the concentration of component (A) and (B) in the target space is 0.1% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, still more preferably 10% by mass or more of the saturation concentration (mass / volume) of the compound in the space. From the viewpoint of reducing the fragrance intensity, it is used so as to volatilize at 100% by mass or less, preferably 50% by mass or less, more preferably 25% by mass or less, still more preferably 20% by mass or less. Also, from the same viewpoint, it is used so as to volatilize at 0.1 to 100% by mass, preferably 1 to 50% by mass, more preferably 5 to 25% by mass, still more preferably 10 to 20% by mass. The concentration of component (A) and (B) in the target space can be detected by measuring the concentration of the compound in the gas collected from the space, and examples of the method include a method using a volatile organic compound concentration measuring device (VOC measuring device, odor sensor, etc.), and a method obtained by using a gas chromatograph or gas chromatograph / mass spectrometry in combination with a gas collection tube, etc.

Example

[0038] Hereinafter, examples will be shown to more specifically explain the present invention. Example 1 Inactivation of influenza virus in liquid phase 1. Method The influenza A virus (A / Puerto Rico / 8 / 1934, H1N1) strain was used as the test virus strain. A solution containing 6% by volume of the compound, 60% by volume of dipropylene glycol (FUJIFILM Wako Pure Chemical Corporation), and 34% by volume of UltraPure DNase / RNase-Free Distilled Water (Thermo Fisher Scientific) was used as the stock solution of the compound and stored at 4°C in a ProteoSafe tube (Sumitomo Bakelite Co., Ltd.) until use. A solution obtained by diluting the stock solution 30-fold with Hybridoma-SFM (SFM; Thermo Fisher Scientific) was added to a 96-well ProteoSafe plate (Sumitomo Bakelite Co., Ltd.) at 60 μL per well, and 60 μL of the virus solution (7.8×10 5 FFU) was added thereto, and the reaction was carried out at room temperature (about 23°C) for 10 minutes or 30 minutes so that the final concentration of the compound was 0.1% by volume.

[0039] The compounds shown in Table 1 were used, and those obtained by combining components (A) and (B) as shown in Tables 2-1 to 2-3 were evaluated. Further, for comparison, those using components (A) and (B) alone, and those using citronellyl formate, 4-methoxybenzyl acetate, L-carboxylic acid (component (B')) instead of component (B) and combining these with component (A) were evaluated. When combining a plurality of compounds, the total concentration was adjusted to 0.1% by volume, for example, for two kinds, it was prepared as 0.05% by volume × 2 and reacted with the virus. Note that the numerical values of the respective components of each composition described in Tables 2-1 to 2-3 represent values converted to the content (% by mass) in the composition.

[0040] After the reaction, the virus was diluted with SFM and infected into MDCK cells (derived from canine renal tubular epithelial cells) that had been cultured in 12- or 48-well plates in advance, and the virus titer was measured by Focus Forming Assay. Specifically, after culturing for about 18 hours under the conditions of 37 °C and 5% (v / v) CO2, the number of formed foci was measured to determine the viral infectivity titer. The infectivity titer when reacted with the control 1% (v / v) dipropylene glycol solution was set as 100%, and the virus inactivation rate (%) (100 - infectivity titer) of each compound was calculated. The test was conducted 1 to 5 times.

[0041]

Table 1

[0042]

Table 2-1

[0043]

Table 2-2

[0044]

Table 2-3

[0045] 2. Results The results are shown together in Tables 2-1 to 2-3. As shown in Tables 2-1 to 2-3, when component (A) and component (B) were used in combination, a more excellent virus-inactivating effect was observed. When cedryl acetate, caryophyllene acetate or citronellyl butyrate was used as component (B), a synergistic virus-inactivating effect was significantly expressed.

Claims

1. A virus inactivator comprising a combination of the following components (A) and (B); (A) Thymol, (B) One or more selected from esters of cedrol represented by the following formula (b1), esters of β-caryophyllene alcohol represented by the following formula (b2), esters of citronellol represented by the following formula (b3), trans-2-undecenal, and interlabenal aldehyde. 【Chemical 1】 [In the formula, R １ , R ２ , R ３ each represents a linear or branched alkyl group or alkenyl group having 1 to 4 carbon atoms. ]

2. An antiviral composition containing the following components (A) and (B); (A) Thymol, (B) One or more selected from esters of cedrol represented by the following formula (b1), esters of β-caryophyllene alcohol represented by the following formula (b2), esters of citronellol represented by the following formula (b3), trans-2-undecenal, and interlabenal aldehyde. 【Chemical 2】 [wherein, R １ , R ２ , R ３ each represents a linear or branched alkyl or alkenyl group having 1 to 4 carbon atoms).]

3. The virus inactivator according to Claim 1, or the antiviral composition according to Claim 2, wherein the virus is an RNA virus having an envelope.

4. The virus inactivator according to Claim 1, or the antiviral composition according to Claim 2, wherein the virus is an influenza virus or a coronavirus.

5. The virus inactivator according to Claim 1, or the antiviral composition according to Claim 2, wherein component (B) is one or more selected from esters of cedrol represented by the above formula (b1), esters of β-caryophyllene alcohol represented by the above formula (b2), and esters of citronellol represented by the above formula (b3).

6. The antiviral composition according to Claim 3 or 4, wherein component (B) is one or more selected from esters of cedrol represented by the above formula (b1), esters of β-caryophyllene alcohol represented by the above formula (b2), and esters of citronellol represented by the above formula (b3).

7. The virus inactivator according to Claim 1, or the antiviral composition according to Claim 2, wherein component (B) is one or more selected from cedryl acetate, caryophyllene acetate, and citronellyl butyrate.

8. The antiviral composition according to Claim 3 or 4, wherein component (B) is one or more selected from cedryl acetate, caryophyllene acetate, and citronellyl butyrate.

9. A virus inactivation method of applying the following component (A) and component (B), or a composition containing these to a subject suspected of being contaminated with a virus; (A) Thymol, (B) At least one selected from esters of cedrol represented by the following formula (b1), esters of β-caryophyllene alcohol represented by the following formula (b2), esters of citronellol represented by the following formula (b3), trans-2-undecenal, and interlabenal aldehyde. [Chemical Formula 3] [In the formula, R １ , R ２ , R ３ each represents a linear or branched alkyl or alkenyl group having 1 to 4 carbon atoms. ]

Images